Peter McAllister
Neurology · Fairfield, CTNPI 1033176896
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by AbbVie at 26.8% of the total. Among neurology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 4,652 payments — averaging $494.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$617K
- Lilly USA, LLC$467K
- H. Lundbeck A S$298K
- Lundbeck LLC$164K
- Teva Pharmaceuticals USA, Inc.$142K
- Amgen$116K
- plus $494K from 54 others
Across 1,844 payments — averaging $6921.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$5.4M
- Ipsen Innovation$965K
- AbbVie$910K
- Genentech, Inc.$772K
- H. Lundbeck A S$771K
- Novartis$533K
- plus $3.4M from 24 others
What the payments were for
- Consulting fees$558,06624%
- Speaking & faculty fees$1,362,47359%
- Grants$880%
- Travel & lodging$296,68213%
- Food & beverage$83,4314%
- Education$5490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYEPTI$411,684
- UBRELVY$281,157
- BOTOX$240,833
- QULIPTA$172,122
- EMGALITY$166,267
- AJOVY$139,508
- KISUNLA$132,043
- REYVOW$116,805
- AIMOVIG$116,253
- Trudhesa$114,003
- NURTEC ODT$69,159
- XEOMIN$45,400
- PURIFIED CORTROPHIN GEL$39,887
- Symbravo$32,456
- TOSYMRA$30,753
- EPTINEZUMAB$19,192
- ELYXYB - CELECOXIB$16,673
- ABILIFY MAINTENA$16,383
- REXULTI$16,383
- BRINTELLIX$16,383
How this compares
$2,301,289 in reported general payments places this provider in the 95th percentile of 280 neurology providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 36 | $450,223 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 35 | $417,122 |
| BotoxOnabotulinumtoxina | 60 | $80,084 |
| QuliptaAtogepant | 46 | $67,562 |
| VyeptiEptinezumab-Jjmr | 13 | $61,183 |
| UbrelvyUbrogepant | 23 | $34,402 |
| AptiomEslicarbazepine Acetate | 12 | $23,968 |
| TrintellixVortioxetine Hydrobromide | 34 | $21,811 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $21,163 |
| Emgality PenGalcanezumab-Gnlm | 23 | $16,257 |
| KeppraLevetiracetam | 11 | $15,828 |
| Sumatriptan Succinate | 92 | $10,580 |
| Zolmitriptan | 12 | $7,888 |
| BelsomraSuvorexant | 13 | $5,559 |
| Duloxetine Hcl | 73 | $1,972 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $424 | $450,22336 claims |
| PfizerOctagam | $36,725 | $417,12235 claims |
| AbbVieBotox, Qulipta, Ubrelvy | $617,038 | $182,048129 claims |
| Lundbeck LLCVyepti | $163,806 | $61,18313 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $342 | $23,96812 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $981 | $21,81134 claims |
| MerckBelsomra | $250 | $5,55913 claims |
| Upsher-smith Laboratories LLCTopiramate | $50,260 | $67232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 280 neurology providers in Connecticut.
Other neurology in Fairfield
- Peter GottschalkFairfield$318K
- Nicholas BlondinFairfield$93K
- Jeffrey GrossFairfield$52K
- Srinath KadimiFairfield$32K
- Stewart TepperStamford$1.2M
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Wanda Castro-BorreroFarmington$553K
- Derek SmithNorwich$469K
- Deena KuruvillaWestport$440K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.